Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 4/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15699830 | 0.92 | SIRT5 (0.39) | MAP1LC3BFURINSIRT5SIRT2SIRT1 | |
| SCHEMBL19687790 | 0.91 | SIRT5 (0.39) | MAP1LC3BFURINSIRT5SIRT2SIRT1 | |
| SCHEMBL19387330 | 0.89 | SIRT5 (0.38) | MAP1LC3BFURINSIRT5SIRT2SIRT1 | |
| SCHEMBL22138596 | 0.88 | FURIN (0.39) | FURINCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL20705515 | 0.88 | FURIN (0.39) | FURINCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL22138594 | 0.88 | FURIN (0.39) | FURINCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL27447192 | 0.88 | FURIN (0.39) | FURINCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL24296990 | 0.88 | FURIN (0.40) | MAP1LC3BFURINSIRT2SIRT1SIRT3 | |
| SCHEMBL23252621 | 0.88 | FAP (0.42) | MAP1LC3BFURINSIRT5SIRT2SIRT1 | |
| SCHEMBL25000070 | 0.87 | SIRT2 (0.38) | MAP1LC3BFURINSIRT5SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | PFIZER INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210061923-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | PFIZER INC. (US) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061923-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | CCNI, TTI1, TTI2 | MAP1LC3B 194/4885FURIN 2289/4885SIRT5 4164/4885 |
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | CCNI, TTI1, TTI2 | MAP1LC3B 194/4885FURIN 2289/4885SIRT5 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.